Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB-6002 Local Infiltration in Healthy Male Adults
NCT06095973Phase 1Completed
- Sponsor
- G2GBIO
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GB-6002 in postoperative pain (4 cohorts), sponsored by G2GBIO. Primary endpoints: Adverse Events, Clinical Laboratory Tests and 3 more. Started Oct 2023; status: completed.
02
Drugs
GB-6002
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06095973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095973.